Head to Head Survey: C R Bard (BCR) and Syneron Medical (NASDAQ:ELOS)

C R Bard (NYSE: BCR) and Syneron Medical (NASDAQ:ELOS) are both companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of recent ratings for C R Bard and Syneron Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C R Bard 0 7 0 0 2.00
Syneron Medical 0 1 0 0 2.00

C R Bard presently has a consensus target price of $310.60, suggesting a potential downside of 6.23%. Syneron Medical has a consensus target price of $11.00, suggesting a potential upside of 0.00%. Given Syneron Medical’s higher probable upside, analysts plainly believe Syneron Medical is more favorable than C R Bard.


This table compares C R Bard and Syneron Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
C R Bard 9.51% 19.39% 6.91%
Syneron Medical -1.09% -1.74% -1.30%

Insider & Institutional Ownership

79.1% of C R Bard shares are held by institutional investors. Comparatively, 69.2% of Syneron Medical shares are held by institutional investors. 0.8% of C R Bard shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


C R Bard pays an annual dividend of $0.78 per share and has a dividend yield of 0.2%. Syneron Medical does not pay a dividend. C R Bard has raised its dividend for 46 consecutive years.

Volatility & Risk

C R Bard has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Syneron Medical has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Earnings and Valuation

This table compares C R Bard and Syneron Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
C R Bard $3.71 billion 6.50 $531.40 million N/A N/A
Syneron Medical N/A N/A N/A N/A N/A

C R Bard has higher revenue and earnings than Syneron Medical.


C R Bard beats Syneron Medical on 8 of the 10 factors compared between the two stocks.

About C R Bard

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

About Syneron Medical

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company’s products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply